The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Interim analysis of anbal-cel for R/R DLBCL
Won-Seog Kim, MD, PhD, Sungkyunkwan University School of Medicine, Seoul, South Korea, discusses a Phase I/II study evaluating anbalcabtagene autoleucel (anbal-cel), an anti-CD19 CAR-T therapy with dual silencing of PD-1 and TIGIT, for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL; NCT04836507). Prof. Kim shares the encouraging efficacy and safety data from the interim analysis of the trial. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
